Latest news with #Cashin
Associated Press
21-05-2025
- Business
- Associated Press
Appia Announces Appointment of Peter J. Cashin as a Director of the Company
Toronto, Ontario--(Newsfile Corp. - May 21, 2025) - Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQB: APAAF) (FSE: A0I0) (MUN: A0I0) (BER: A0I0) (the 'Company' or 'Appia') wishes to announce that Peter J. Cashin has been appointed to the Board of Directors of the Company to fill the vacancy created by the passing of Thomas Skimming. Tom Drivas, CEO and Interim President, stated, 'We are very pleased that Peter has agreed to join the Board of Directors of Appia. Peter brings a wealth of experience to the Board and we look forward to his input.' Mr. Cashin is a respected minerals industry executive with over 40 years experience in all facets of the Canadian and International mining exploration and development sector. Peter currently operates a mineral sector consultancy, Apex Mineral Consultants Inc., providing exploration and development technical advisory services for the critical mineral and material sectors. Peter is an established mining sector executive as the Founder and President & CEO of both Imperial Mining Group Ltd. (TSXV: IPG) from 2018 to 2024 and Quest Rare Minerals Ltd. (TSXV: QRM) from 2008 to 2015. It was with Quest in 2009 that he had his greatest career success with the discovery and development of the Strange Lake B-Zone rare earth deposit in northeastern Quebec, considered the largest deposit of its type in the world outside of China. The discovery's significance was acknowledged by the Quebec Mineral Exploration Association in 2010 with the awarding of The Quebec Prospector of the Year Award to Peter and his Team. Mr. Cashin obtained his Bachelor of Science in Geology from the University of New Brunswick in 1979 and a Master of Science degree in Mineral Exploration from McGill University in 1985. Peter was born and raised north of Montreal, Quebec and currently lives with his family in Burlington, Ontario, Canada. Mr. Cashin has been a Practicing Professional Geoscientist with Professional Geoscientists Ontario (PGO) since 2008. It is with great sadness that we acknowledge the passing of Thomas Skimming. Thomas was a director of the Company from its inception in 2009. His depth of geological knowledge along with his warmth, charm and humour will be greatly missed. The Board of Directors extends its deepest condolences to his family. Mr. Cashin's appointment as a Director is subject to acceptance by the Canadian Securities Exchange (CSE). Mr. Cashin has been granted 500,000 stock options exercisable at $0.15 per share for five years vesting over a period of six months. About Appia Rare Earths & Uranium Corp. (Appia) Appia is a publicly traded Canadian company in the rare earth element and uranium sectors. The Company holds the right to acquire up to a 70% interest in the PCH Ionic Adsorption Clay Project (See June 9 th, 2023 Press Release - ClickHERE ) which is 42,932.24 hectares in size and located within the Goiás State of Brazil (See January 11 th, 2024 Press Release - Click HERE ). The Company is also focusing on delineating high-grade critical rare earth elements and gallium on the Alces Lake property, and exploring for high-grade uranium in the prolific Athabasca Basin on its Otherside, Loranger, North Wollaston, and Eastside properties. The Company holds the surface rights to exploration for 94,982.39 hectares (234,706.59 acres) in Saskatchewan. The Company also has a 100% interest in 13,008 hectares (32,143 acres), with rare earth elements and uranium deposits over five mineralized zones in the Elliot Lake Camp, Ontario. Appia has 153 million common shares outstanding, 177 million shares fully diluted. Cautionary note regarding forward-looking statements: This News Release contains forward-looking statements which are typically preceded by, followed by or including the words 'believes', 'expects', 'anticipates', 'estimates', 'intends', 'plans' or similar expressions. Forward-looking statements are not a guarantee of future performance as they involve risks, uncertainties and assumptions. We do not intend and do not assume any obligation to update these forward-looking statements and shareholders are cautioned not to put undue reliance on such statements. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. For more information, book a one-on-one 30-minute Zoom video call, please click here. Contact: Tom Drivas, CEO and Director (c) (416) 876-3957 (e) [email protected] To view the source version of this press release, please visit
Yahoo
20-03-2025
- Health
- Yahoo
Just 1 in 10 back pain treatments work, study says — what to do instead
Chronic back pain is the most common type of pain, affecting around 16 million American adults — and now a new study has revealed some discouraging findings about potential treatments. Only around one in every 10 treatments was found to be effective in relieving lower back pain, according to a new study published in BMJ Evidence-Based Medicine. Many of them are "barely better than a placebo" in terms of pain relief, as stated in a press release from the University of New South Wales (UNSW) in Sydney, Australia. 'Dead Butt Syndrome' Could Happen After Sitting Too Long, Here's How To Avoid The Condition "Our review did not find reliable evidence of large effects for any of the included treatments," said lead study author Dr. Aidan Cashin, deputy director of the Centre for Pain IMPACT at Neuroscience Research Australia (NeuRA) and conjoint senior lecturer in the School of Health Sciences at UNSW Sydney. The researchers reviewed 301 randomized, controlled trials that included data on 56 non-surgical treatments for adults experiencing acute low back pain, chronic low back pain or a combination of both types, comparing them to groups that received placebos. Read On The Fox News App "Treatments included in the research were pharmacological, such as non-steroidal anti-inflammatory drugs – or NSAIDs – and muscle relaxants, but also non-pharmacological, like exercise and massage," Cashin said. Ineffective treatments for acute low back pain included exercise, steroid injections and paracetamol (acetaminophen), the study found. For chronic low back pain, antibiotics and anaesthetics were also "unlikely to be suitable treatment options," the study found. For acute low back pain, non-steroidal anti-inflammatory drugs (NSAIDs) could be effective, the study found. For chronic low back pain, therapies including exercise, taping, spinal manipulation, antidepressants and transient receptor potential vanilloid 1 (TRPV1) agonists may be effective — "however, those effects were small," Cashin noted. The findings were "inconclusive" for many other treatments due to the "limited number of randomized participants and poor study quality," the researchers stated. "We need further high-quality, placebo-controlled trials to understand the efficacy of treatments and remove the uncertainty for both patients and clinical teams," Cashin said. Dr. Stephen Clark, a physical therapist and chief clinical officer at Confluent Health in Georgia, noted that the study was looking at "isolated interventions." "They excluded studies where it was not possible to isolate the effectiveness of the target intervention," Clark, who was not involved in the study, told Fox News Digital. Pain is a complex condition influenced by many different factors, according to Clark. "Determining a specific cause of low back pain, particularly when the pain is persistent, is difficult, as the BMJ study points out," he said. "Things like stress, sleep quality, fatigue, fear, social situations, nutrition, sickness and previous history of pain all play a role in how we experience pain." Clark recommends "multimodal" treatments for pain, including multiple interventions tailored to each individual patient's experience. Click Here To Sign Up For Our Health Newsletter "Physical therapy research shows that manual therapy (joint mobilization/manipulation, soft tissue techniques), active interventions like exercise, and education about why you hurt and what to do about it is the ticket," he said. "It's also important to remember that what worked for someone else might not be the exact pathway that works for you." While surgical intervention can be effective for some patients, Clark noted that it can present its own challenges and should be a "last resort" for non-emergency situations. For more Health articles, visit "While surgery is indicated in some cases, it's almost never the answer in isolation," he said. "Understanding pain and the complexity around a person's situation must be in view." "In many cases, conservative care can prevent or delay the need for invasive procedures."Original article source: Just 1 in 10 back pain treatments work, study says — what to do instead
Fox News
20-03-2025
- Health
- Fox News
Just 1 in 10 back pain treatments work, study says — what to do instead
Chronic back pain is the most common type of pain, affecting around 16 million American adults — and now a new study has revealed some discouraging findings about potential treatments. Only around one in every 10 treatments was found to be effective in relieving lower back pain, according to a new study published in BMJ Evidence-Based Medicine. Many of them are "barely better than a placebo" in terms of pain relief, as stated in a press release from the University of New South Wales (UNSW) in Sydney, Australia. "Our review did not find reliable evidence of large effects for any of the included treatments," said lead study author Dr. Aidan Cashin, deputy director of the Centre for Pain IMPACT at Neuroscience Research Australia (NeuRA) and conjoint senior lecturer in the School of Health Sciences at UNSW Sydney. The researchers reviewed 301 randomized, controlled trials that included data on 56 non-surgical treatments for adults experiencing acute low back pain, chronic low back pain or a combination of both types, comparing them to groups that received placebos. "Treatments included in the research were pharmacological, such as non-steroidal anti-inflammatory drugs – or NSAIDs – and muscle relaxants, but also non-pharmacological, like exercise and massage," Cashin said. Ineffective treatments for acute low back pain included exercise, steroid injections and paracetamol (acetaminophen), the study found. For chronic low back pain, antibiotics and anaesthetics were also "unlikely to be suitable treatment options," the study found. For acute low back pain, non-steroidal anti-inflammatory drugs (NSAIDs) could be effective, the study found. For chronic low back pain, therapies including exercise, taping, spinal manipulation, antidepressants and transient receptor potential vanilloid 1 (TRPV1) agonists may be effective — "however, those effects were small," Cashin noted. "Things like stress, sleep quality, fatigue, fear, social situations, nutrition, sickness and previous history of pain all play a role in how we experience pain." The findings were "inconclusive" for many other treatments due to the "limited number of randomized participants and poor study quality," the researchers stated. "We need further high-quality, placebo-controlled trials to understand the efficacy of treatments and remove the uncertainty for both patients and clinical teams," Cashin said. Dr. Stephen Clark, a physical therapist and chief clinical officer at Confluent Health in Georgia, noted that the study was looking at "isolated interventions." "They excluded studies where it was not possible to isolate the effectiveness of the target intervention," Clark, who was not involved in the study, told Fox News Digital. Pain is a complex condition influenced by many different factors, according to Clark. "Determining a specific cause of low back pain, particularly when the pain is persistent, is difficult, as the BMJ study points out," he said. "Things like stress, sleep quality, fatigue, fear, social situations, nutrition, sickness and previous history of pain all play a role in how we experience pain." Clark recommends "multimodal" treatments for pain, including multiple interventions tailored to each individual patient's experience. "Physical therapy research shows that manual therapy (joint mobilization/manipulation, soft tissue techniques), active interventions like exercise, and education about why you hurt and what to do about it is the ticket," he said. "It's also important to remember that what worked for someone else might not be the exact pathway that works for you." While surgical intervention can be effective for some patients, Clark noted that it can present its own challenges and should be a "last resort" for non-emergency situations. For more Health articles, visit "While surgery is indicated in some cases, it's almost never the answer in isolation," he said. "Understanding pain and the complexity around a person's situation must be in view." "In many cases, conservative care can prevent or delay the need for invasive procedures."
New York Times
07-02-2025
- Sport
- New York Times
Brighton's Eiran Cashin ready for Premier League step up
Brighton & Hove Albion head coach Fabian Hurzeler believes January signing Eiran Cashin is equipped with and without the ball to make the step up to the Premier League. Cashin, 23, has swapped a relegation fight with Derby County in the Championship for a move to the Amex Stadium for a £9million fee, on a contract until 2030. Advertisement The former Republic of Ireland youth international, a long-time Brighton target, becomes the third outfield player in Hurzeler's squad to move up from England's second tier. Fellow central defender Adam Webster was signed from Bristol City in August 2019, while forward Georginio Rutter arrived from Leeds United last summer. Hurzeler said of Cashin: 'In possession, he is a player with a very good left foot. He can break lines with his passes. He is very clever when he makes a decision to find a pass. He always finds a free team-mate, he doesn't put a team-mate under pressure. He finds a team-mate who can continue the game forward, so that is a special quality. 'On top of that, he is very aggressive against the ball. He likes to have personal duels. He is not hiding from making the last step, so I knew that the club wanted to have him for a long time. We've observed him and now was the chance to sign him and we are all happy.' GO DEEPER Eiran Cashin - the old-school Derby centre-back who has rare gift in modern game Cashin is in line for a place on the bench for Saturday's FA Cup fourth round tie at home to Chelsea. Webster is set to compete for a starting role with regular duo Lewis Dunk and Jan Paul van Hecke, who featured in last Saturday's 7-0 thrashing at Nottingham Forest. Hurzeler said: 'The percentage that he (Cashin) will start the game is not that high, but he will be in the squad and he will be an option.' Carlos Baleba, midfield partner Yasin Ayari and left-back Pervis Estupinan remain doubts after missing Brighton's heaviest ever Premier League defeat at Forest. 'One game shouldn't define our season, shouldn't define our whole team,' Hurzeler said. 'One of our basics is to play with intensity. We missed this in the last game.' GO DEEPER Brighton's transfer window: Cashin, Ferguson and two trademark summer deals part of busy January (MI News/NurPhoto via Getty Images)
New York Times
06-02-2025
- Business
- New York Times
Eiran Cashin to Brighton & Hove Albion: The Athletic 500 transfer ratings
Brighton & Hove Albion strengthened their defence in the winter transfer window by signing Eiran Cashin from Derby County on a deal worth £9million (€10.8m/$11.2m). Our writers — experts in transfers, tactics, data and football finance — have come together to rate January's senior Premier League transfers. This continues the project we launched last summer, but we have also made some significant tweaks to how we assess each deal. Advertisement Gone are the five scores out of 100, and in their place are 10 ratings out of 50. This should allow for much more nuance to be reflected in the analysis and, importantly, much more variability in the overall figure each transfer ends up with. Follow the link below for more background on the changes. GO DEEPER The Athletic 500: What we learned and why we've changed our transfer scoring system Cashin adds height and good on-the-ball ability to Brighton's beleaguered back line. Fabian Hurzeler's team have been one of the worst from set pieces in the Premier League this season, struggling to score from them at one end and keep them out at the other. Cashin is prolific in the air, winning 67 per cent of his 5.3 aerial duels per 90 minutes in the Championship this season. He uses his physicality well to outmuscle attackers on the ground too. In possession, Cashin prefers to pass with his stronger left foot and is capable of finding wide players with diagonal passes. He can play shorter passes with his right foot too, making him an asset in the build-up. Cashin is not the quickest defender, which could hurt Brighton defensively given the high line they deploy, especially in transitions. But he makes up for it with his smart positioning: his 2.2 interceptions per 90 is the best among all Championship defenders this season. Cashin's ball-carrying is an area that requires improvement too, but overall, this is a signing that will help Brighton in the short and long term. Cashin suffered the first major injury of his senior career in December 2024, with a hamstring problem ruling him out for a month. Apart from that, he has had a mostly clean slate, featuring in 87 of 92 league matches for Derby County across the 2022-23 and 2023-24 seasons. A fee of £9million for a player yet to enter his peak years is excellent value for money. Cashin does not have any top-flight experience, spending most of his short career in League One, so this will be a big leap but his familiarity with the physicality of English football should help. Cashin has been handed a five-and-a-half-year contract, which makes sense for both parties given he is only 23 and just entering his best years as a professional, even if doubts will persist over his readiness for the Premier League. Cashin started 19 of Derby's 21 Championship matches prior to his hamstring injury in December, scoring once and helping Derby keep six clean sheets. They did not manage a clean sheet without him in the lineup, dropping from 14th when he got injured to 18th by the time he returned in January. His final two appearances for the club resulted in defeats to Watford and Cardiff City, leaving Derby in the relegation zone. Brighton have faced an injury crisis at centre-back this season and the need to bolster their depth was evident. Igor Julio is out for the season after undergoing hamstring surgery, while Adam Webster spent nearly three months on the sidelines towards the end of 2024 with a thigh injury. Club captain Lewis Dunk missed roughly two weeks of action in January with a calf issue too. Additionally, with Dunk and Webster out of contract in the summer of 2026, signing Cashin alleviates both short-term and long-term concerns. Given the club's requirements at centre-back and the fact that Cashin was a long-term Brighton target before Hurzeler's arrival, this deal will be pleasing to many fans. But there will be doubts over his ability to immediately contribute in the Premier League. A five-and-a-half-year contract secures Cashin's long-term future, while Brighton will ideally see him play out his peak years with them, knowing that they will stand a chance of profiting from a future sale too. The contract situation of their other centre-backs makes this a no-brainer too. Not many clubs were linked with Cashin, and this is not a signing that will prompt much reaction among Brighton's Premier League rivals. Brighton will not mind, though, as it addresses an important squad need. It is difficult to see Cashin's arrival massively impacting the plans of Brighton's marketing team. (Header photo: Getty Images)
